FDA Comes Under Scrutiny

<p><em>Health Affairs</em>' Michael Gerber and Rob Lott discuss the latest developments at the FDA, including the first oral treatment for postpartum depression, the Accelerated Approval Program, and the agency being namechecked on the GOP presidential campaign trail.</p><p><strong>Related Links:</strong></p><ul> <li> <a href="https://www.healthaffairs.org/content/forefront/create-economic-incentive-timely-completion-confirmatory-trials?utm_medium=podcast&amp;utm_source=this+week">Create An Economic Incentive For The Timely Completion Of Confirmatory Trials</a> (<em>Health Affairs Forefront</em>)</li> <li>T<a href="https://www.healthaffairs.org/content/forefront/conundrum-patient-access-therapeutic-medical-devices?utm_medium=podcast&amp;utm_source=this+week">he Conundrum Of Patient Access To Therapeutic Medical Devices</a> (<em>Health Affairs Forefront</em>)</li> <li><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression">FDA Approves First Oral Treatment for Postpartum Depression </a></li> <li><a href="https://www.healthaffairs.org/request-for-abstracts/reimagining-public-health?utm_medium=podcast&amp;utm_source=this+week">Request For Abstracts - Reimagining Public Health</a></li> <li><a href="https://www.healthaffairs.org/request-for-abstracts/2024-perinatal-mental-health?utm_medium=podcast&amp;utm_source=this+week">Request For Abstracts - Perinatal Mental Health</a></li> </ul><p>C<em>urrently, more than 70 percent of our content is freely available — and we’d like to keep it that way. </em><a href="https://www.healthaffairs.org/subscribe/individual?utm_medium=podcast&amp;utm_source=this+week&amp;utm_campaign=individual+subscriptions"><em>With your support,</em></a> <em>we can continue to keep our digital publication Forefront</em> <em>and podcasts free for everyone.</em></p>